<DOC>
	<DOCNO>NCT01875523</DOCNO>
	<brief_summary>The study design evaluate pharmacokinetics , safety tolerability , immunogenicity pharmacogenetics single dose serelaxin/RLX030 patient severe renal impairment end-stage-renal-disease ( ESRD ) compare healthy volunteer .</brief_summary>
	<brief_title>PK Serelaxin Severe Renal Impairment ESRD</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Inclusion criterion : All subject least 50 year ; body mass index ( BMI ) within range 18 35 kg/m2 . Patients severe renal impairment / ESRD Severe renal impairment ( clinically significantly abnormal creatinine creatinine clearance ( 15mL/min/1.73m2≤eGFR &lt; 30mL/min/1.73m2 ) ESRD hemodialysis . Sitting vital sign within follow range : oral body temperature 35.037.5 °C systolic blood pressure , 110 170 mm Hg diastolic blood pressure , 60 105 mm Hg pulse rate , 45 100 bpm Healthy subject eGFR &gt; 90mL/min/1.73m2 ; match race , age ( ±10 year ) , gender , BMI ( ±15 % ) subject renal impairment Subject must good health . Sitting vital sign within follow range : oral body temperature 35.037.5 °C systolic blood pressure , 100 150 mm Hg diastolic blood pressure , 60 95 mm Hg pulse rate , 50 100 bpm All subject History clinically significant ECG abnormality Screening Baseline . Pregnant nursing ( lactate ) woman Women childbearing potential unless use highly effective method contraception dose study treatment . Sexually active male ( incl . vasectomize men ) must use condom intercourse take drug 2 week stop study medication . Recent ( within last three year ) and/or recurrent history autonomic dysfunction ( e.g. , recurrent episode fainting , palpitation , etc. ) . Patients severe renal impairment / ESRD : Presence noncontrolled clinically significant disease , surgical medical condition could affect study outcome would place patient undue risk judge investigator . Hemoglobin level 9.0 g/dL screen baseline , laboratory parameter screen baseline outside acceptable limit . Treatment cytostatic drug autonomic alpha blocker . Healthy subject : Use prescription drug ( hormonal contraception , herbal supplement , within four ( 4 ) week prior initial dosing , and/or overthecounter ( OTC ) medication , dietary supplement ( vitamin include ) within two ( 2 ) week prior initial dosing . History presence disease , surgical medical condition major system organ class consider clinically significant investigator . Laboratory parameter screen baseline outside normal limit . For small deviation could attribute characteristic subject ( e.g . age ) discretion investigator consider exclusive . A positive Hepatitis B surface antigen Hepatitis C test result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Renal disease</keyword>
	<keyword>renal impairment</keyword>
	<keyword>End stage renal disease</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>